603 related articles for article (PubMed ID: 18395387)
1. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
2. F-18 FDG PET/CT in the management of thyroid cancer.
Iagaru A; Kalinyak JE; McDougall IR
Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
[TBL] [Abstract][Full Text] [Related]
3. Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions.
Imbriaco M; Caprio MG; Limite G; Pace L; De Falco T; Capuano E; Salvatore M
AJR Am J Roentgenol; 2008 Nov; 191(5):1323-30. PubMed ID: 18941064
[TBL] [Abstract][Full Text] [Related]
4. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
5. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.
Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H
J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269
[TBL] [Abstract][Full Text] [Related]
7. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of a breath-holding acquisition method in PET/CT for pulmonary lesions.
Yamaguchi T; Ueda O; Hara H; Sakai H; Kida T; Suzuki K; Adachi S; Ishii K
Ann Nucl Med; 2009 Jan; 23(1):65-71. PubMed ID: 19205840
[TBL] [Abstract][Full Text] [Related]
9. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
10. FDG PET-CT in the management of primary breast lymphoma.
Santra A; Kumar R; Reddy R; Halanaik D; Kumar R; Bal CS; Malhotra A
Clin Nucl Med; 2009 Dec; 34(12):848-53. PubMed ID: 20139815
[TBL] [Abstract][Full Text] [Related]
11. Tumor volume assessment by 18F-FDG PET/CT in patients with oral cavity cancer with dental artifacts on CT or MR images.
Baek CH; Chung MK; Son YI; Choi JY; Kim HJ; Yim YJ; Ko YH; Choi J; Cho JK; Jeong HS
J Nucl Med; 2008 Sep; 49(9):1422-8. PubMed ID: 18703597
[TBL] [Abstract][Full Text] [Related]
12. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
13. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
Tsujikawa T; Otsuka H; Morita N; Saegusa H; Kobayashi M; Okazawa H; Nishitani H
Ann Nucl Med; 2008 Jan; 22(1):23-30. PubMed ID: 18250984
[TBL] [Abstract][Full Text] [Related]
14. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study.
Iagaru A; Mittra E; Yaghoubi SS; Dick DW; Quon A; Goris ML; Gambhir SS
J Nucl Med; 2009 Apr; 50(4):501-5. PubMed ID: 19289439
[TBL] [Abstract][Full Text] [Related]
15. Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma.
Falk MS; Truitt AK; Coakley FV; Kashani-Sabet M; Hawkins RA; Franc B
Nucl Med Commun; 2007 Apr; 28(4):273-80. PubMed ID: 17325590
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer.
Sato M; Okumura T; Kaito K; Kiyoshima M; Asato Y; Uchiumi K; Iijima H; Hashimoto I; Kaburagi T; Amemiya R
Ann Nucl Med; 2009 Jan; 23(1):49-57. PubMed ID: 19205838
[TBL] [Abstract][Full Text] [Related]
17. Objective and subjective comparison of standard 2-D and fully 3-D reconstructed data on a PET/CT system.
Strobel K; Rüdy M; Treyer V; Veit-Haibach P; Burger C; Hany TF
Nucl Med Commun; 2007 Jul; 28(7):555-9. PubMed ID: 17538397
[TBL] [Abstract][Full Text] [Related]
18. Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-fluoro-2-deoxy-D-glucose avidity on positron emission tomography/computed tomography.
Bar-Shalom R; Kagna O; Israel O; Guralnik L
Cancer; 2008 Dec; 113(11):3213-21. PubMed ID: 18924145
[TBL] [Abstract][Full Text] [Related]
19. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients.
Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Ohbayashi C; Sugimura K
J Magn Reson Imaging; 2007 Oct; 26(4):1071-80. PubMed ID: 17896365
[TBL] [Abstract][Full Text] [Related]
20. Solitary pulmonary nodules: morphological and metabolic characterisation by FDG-PET-MDCT.
Orlacchio A; Schillaci O; Antonelli L; D'Urso S; Sergiacomi G; Nicolì P; Simonetti G
Radiol Med; 2007 Mar; 112(2):157-73. PubMed ID: 17361379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
